Revance Therapeutics, Inc. Stock News

PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, Revance disclosed in a filing with the U....

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a notice to reme...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Revance investments or wo...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $6.66 in cash for each share of Revance that they own. KSF ...

MILWAUKEE , Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation https://www.ademilaw.com/case/revance-therapeutics-inc-0 or call Guri Ademi toll-free at 866-264-3995.

NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Revance Therapeutics, Inc. (NASDAQ: RVNC) and its board of directors concerning the proposed acquisition of the company by Crown Laboratories, Inc. Stockholders will receive $6.66 for each share of Revance Therapeutics stock that they hold. The transaction is valued at approximately ...